NextPlat (NASDAQ:NXPL) reported $2.87 million in sales this quarter. This is a 46.78 percent increase over sales of $1.96 million the same period last year.
Dupixent Application For Treatment Of Chronic Spontaneous Urticaria In Adults And Adolescents Accepted For FDA Review
Dupixent® (dupilumab) application for treatment of chronic spontaneous urticaria (CSU) in adults and adolescents accepted for FDA review
More than 300,000 people in the